Drug discovery

#Business #Drug discovery #Investment #Mergers and acquisitions

Five key drug discovery deals of summer 2023

The life sciences sector has seen significant M&A activity over the last few weeks. DDW’s Diana Spencer provides an overview. BioIVT acquires PrecisionMed In July BioIVT acquired biospecimens company PrecisionMed, gaining access to, reportedly, the largest private, global repository of longitudinally collected human CSF for scientific… Read More

#Business & Investment #Editor's Choice #News

Genetic research
#CAR-T #Drug development #Drug discovery #Synthetic biology

Synthetic biology: Innovating in drug discovery

Listen to this article on the DDW Podcast: Synthetic biology is increasingly important to drug discovery and development. Reece Armstrong examines recent activity within the sector and highlights some of the key advancements and innovation. Partnerships Earlier this year cell-engineering company MaxCyte signed… Read More

#Exclusive Content

Heart health concept
#Drug discovery #Heart attack #Regenerative Medicine #Stem cells #Turning Science into Business

Turning Science into Business: Can regenerative medicine treat heart attacks?   

DDW’s Reece Armstrong speaks to Hendrik Streefkerk, Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases.   Based in France, CellProthera is a small, regenerative cell… Read More

#Exclusive Content

Biologics research
#Biologics #Drug development #Drug discovery #Guide #Monoclonal antibodies #Screening

Guide: Assessing thermal stability with nanoDSF

A new Guide ‘The biologics researcher’s mini-guide to screening candidates with nanoDSF’ is now available from NanoTemper. Among the most common critical quality attributes (CQAs) for early developability assessment is thermal stability. One particular tool for assessing thermal stability with high resolution is nano-differential scanning fluorimetry (nanoDSF). Read More

#News

#Biologics #Drug development #Drug discovery #Guide #Monoclonal antibodies #Screening

The biologics researcher’s mini-guide to screening candidates with nanoDSF

Among the most common critical quality attributes (CQAs) for early developability assessment is thermal stability. One particular tool for assessing thermal stability with high resolution is nano-differential scanning fluorimetry (nanoDSF). Read this mini-guide to learn: How nanoDSF uses your protein’s intrinsic fluorescence to determine its melting temperature, Tm and onset… Read More

#Intelligence #Resources

Antibodies
#Antibodies #Drug discovery #eBook

eBook: Breakthroughs accelerating therapeutic antibodies

The latest eBook by DDW is out now. This 24-page eBook sponsored by Carterra examines the market for therapeutic antibodies and the breakthroughs driving drug discovery in this sector. Download this exclusive eBook to learn more about: The market for therapeutic antibodies Advancements and challenges in the sector Trends… Read More

#News

The microbiome
#Drug discovery #Gut microbiome #Microbiome #Precision medicine

The microbiome in precision medicine

Listen to this article on the DDW Podcast: An industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development. By Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio. Read More

#Exclusive Content #Trends & Analysis

DDW Antibodies eBook
#Antibodies #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Drug development #Drug discovery

Antibody discovery: Breakthroughs accelerating therapeutic antibodies

This 24-page eBook sponsored by Carterra examines the market for therapeutic antibodies and the breakthroughs driving drug discovery in this sector. Download this exclusive eBook to learn more about: The market for therapeutic antibodies Advancements and challenges in the sector Trends in the antibody-drug conjugate (ADC) market… Read More

#DDW eBooks #Intelligence

Drug discovery
#Drug discovery #Medicines Discovery Catapult (MDC)

New podcast on bridging the gaps in drug discovery

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with… Read More

#News

AI drug discovery
#AI / data analytics / healthtech / informatics #Drug discovery #Funding #Investment #Recursion

Nvidia invests $50 million into Recursion for drug AI 

Recursion, a clinical stage company decoding biology to industrialise drug discovery, has announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE).   Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry,… Read More

#News

#Antibodies #Drug development #Drug discovery #Guide

DDW Therapeutic Antibody Guide

Download the exclusive Guide and read about: The future of therapeutic antibodies From the top: Shining the spotlight on an industry leader The major disease areas for therapeutic antibodies… Read More

#DDW eBooks #DDW Guides

Gene editing
#bit bio #CRISPR #Drug discovery #Stem cells #Synthetic biology #Synthetic DNA

Synthetic biology: Impacting drug discovery

Listen to this article on the DDW Podcast: Mark Kotter, Founder and CEO of bit.bio, talks with Reece Armstrong about different approaches to synthetic biology and its applications in programming stem cells into mature, functional human cells for drug discovery and the creation of next… Read More

#Exclusive Content

Cone snails
#Drug development #Drug discovery #University of Queensland

Cone snail venom discovery opens up new leads for drugs

Researchers have reared deadly cone snails in a laboratory aquarium for the first time, uncovering new venoms for drug development. Professor Richard Lewis, Dr Aymeric Rogalski and Dr Himaya Siddhihalu Wickrama Hewage from University of Queensland’s (UQ) Institute for Molecular Bioscience study venoms as therapeutics, and… Read More

#News

Sleeping sickness parasite
#Drug discovery #Novartis #Parasitic disease #University of Glasgow

Compound discovery has breakthrough potential for parasitic disease

Scientists have discovered a new class of compound that is potentially active against trypanosome parasites that cause human African trypanosomiasis (or sleeping sickness) and Chagas disease. The findings – led by researchers at the University of Glasgow and Novartis Global Health (formerly Novartis Institutes for Tropical… Read More

#News

Oncology Research Concept
#Cancer research #Drug discovery #Haematology #Oncology

Q&A with Mark Garner: The golden age of cancer research  

Mark Garner, PhD., Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research.  RA: Please can you tell us a bit more about your role at Agilent?… Read More

#Exclusive Content